Separately, BidaskClub cut Lantheus from a “sell” rating to a “strong sell” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $29.00.
Shares of NASDAQ:LNTH opened at $16.64 on Friday. Lantheus has a 52-week low of $16.42 and a 52-week high of $29.80. The stock has a market cap of $660.15 million, a price-to-earnings ratio of 19.13 and a beta of 1.43. The company has a quick ratio of 2.08, a current ratio of 2.59 and a debt-to-equity ratio of 1.84. The business has a 50-day moving average price of $18.49 and a 200-day moving average price of $20.80.
In related news, CFO Robert J. Jr. Marshall sold 6,351 shares of Lantheus stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $20.82, for a total transaction of $132,227.82. Following the completion of the transaction, the chief financial officer now directly owns 53,428 shares in the company, valued at $1,112,370.96. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Mary Anne Heino sold 19,260 shares of Lantheus stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $20.85, for a total value of $401,571.00. Following the transaction, the chief executive officer now owns 563,034 shares of the company’s stock, valued at $11,739,258.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 37,119 shares of company stock valued at $767,411. Company insiders own 2.60% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC acquired a new position in Lantheus during the fourth quarter worth $320,000. UBS Asset Management Americas Inc. boosted its stake in Lantheus by 28.9% during the fourth quarter. UBS Asset Management Americas Inc. now owns 39,514 shares of the medical equipment provider’s stock worth $810,000 after buying an additional 8,850 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Lantheus by 32.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 150,407 shares of the medical equipment provider’s stock worth $3,085,000 after buying an additional 36,963 shares during the last quarter. UBS Group AG boosted its stake in Lantheus by 77.6% during the fourth quarter. UBS Group AG now owns 52,670 shares of the medical equipment provider’s stock worth $1,081,000 after buying an additional 23,008 shares during the last quarter. Finally, Public Sector Pension Investment Board boosted its stake in Lantheus by 98.4% during the fourth quarter. Public Sector Pension Investment Board now owns 196,695 shares of the medical equipment provider’s stock worth $4,034,000 after buying an additional 97,542 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Recommended Story: How Investors Can Profit from Options Trading
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.